5437-48-9

Basic information

• Product Name: 2-AMINO-1-PIPERIDIN-1-YL-ETHANONE HCL
• Synonyms: 2-AMINO-1-PIPERIDIN-1-YL-ETHANONE HCL;2-AMINO-1-PIPERIDIN-1-YL-ETHANONE HYDROCHLORIDE;2-oxo-2-piperidin-1-ylethanamine;2-Amino-1-Piperidin-1-yl-Ethan;2-AMINO-1-PIPERIDIN-1-YL-ETHANONE X HCL >98%;2-AMINO-1-PIPERIDIN-1-YL-ETHANONE X HCL;2-AMino-1-(1-piperidinyl)-ethanone HCl;2-amino-1-(1-piperidinyl)Ethanone hydrochloride
• CAS NO: 5437-48-9
• Molecular Formula: C₇H₁₄N₂O*ClH
• Molecular Weight: 178.66
• Product Categories: Piperidine;Piperazine
• Mol File: 5437-48-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 311.2 °C at 760 mmHg
• Flash Point: 142 °C
• Appearance: /
• Vapor Pressure: 0.000422mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-AMINO-1-PIPERIDIN-1-YL-ETHANONE HCL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-1-PIPERIDIN-1-YL-ETHANONE HCL(5437-48-9)
• EPA Substance Registry System: 2-AMINO-1-PIPERIDIN-1-YL-ETHANONE HCL(5437-48-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 5437-48-9(Hazardous Substances Data)

Usage

General Description

2-Amino-1-Piperidin-1-yl-Ethanone HCL, also known as 1-Acetyl-2-Aminopiperidine Hydrochloride, is a chemical compound with the molecular formula C7H15ClN2O. It is typically in the form of a white crystalline powder. This chemical is primarily used in various fields of organic chemistry, serving as a significant intermediate in the synthesis of several types of pharmaceuticals and biologically active compounds. It is typically handled and stored under controlled conditions to maintain its stability, purity, and to prevent hazardous reactions. As with any chemical, care must be taken when handling to avoid direct contact or inhalation, as it may pose health risks. Its exact properties such as melting point, boiling point, or potential toxicity levels may vary and should be referenced from detailed chemical data sources.

InChI:InChI=1/C7H14N2O.ClH/c8-6-7(10)9-4-2-1-3-5-9;/h1-6,8H2;1H

Upstream product

• 110-89-4 piperidine 
• 88621-47-0 N-<((tert-butoxycarbonyl)amino)acetyl>piperidine 

Downstream Products

• 58792-06-6 1-[5-(4-chloro-phenoxymethyl)-[1,2,3]thiadiazole-4-carbonyl]-piperidine 
• 116005-79-9 N-cyclohexyl-N-methyl-4-[2-amino-3-(1-piperidinylcarbonylmethyl)-3,4-dihydroquinazolin-6-yl]oxybutyramide hydrobromide 
• 58792-04-4 1-(5-phenoxymethyl-[1,2,3]thiadiazole-4-carbonyl)-piperidine 
• 58792-08-8 1-[5-(3,4-dichloro-phenoxymethyl)-[1,2,3]thiadiazole-4-carbonyl]-piperidine 
• 58792-10-2 1-[5-(4-methoxy-phenoxymethyl)-[1,2,3]thiadiazole-4-carbonyl]-piperidine 
• 58792-18-0 1-[5-(4-chloro-phenoxymethyl)-[1,2,3]thiadiazol-4-ylmethyl]-piperidine 
• 51076-99-4 N-(2-oxo-2-piperidinoethyl)toluene-p-sulphonamide 

Relevant articles and documents

Inhibitors of Cyclic AMP Phosphodiesterase. 4. Synthesis and Evaluation of Potential Prodrugs of Lixazinone (N-Cyclohexyl-N-methyl-4quinazolin-7-yl)oxy>butyramide, RS-82856)

The cyclic AMP phosphodiesterase (cAMP PDE) inhibitor and cardiotonic agent lixazinone (N-cyclohexyl-N-methyl-4-quinazolin-7-yl)oxy>butyramide, RS-82856, 1) and its acid and base addition salts were found to be insufficiently soluble in formulations suitable for intravenous administration.These results prompted an investigation into potential prodrugs with enhanced aqueous solubility designed to deliver 1 by three distinct mechanisms: (1) decarboxylation of α-carboxamides; (2) hydrolytic loss of a solubilizing N-1-(acyloxy)methyl or (N,N-dialkylamino)methyl moiety; or (3) intramolecular closure of a guanidino ester or amide.The target compounds were evaluated as delivery systems for 1 by three criteria: (1) chemical conversion rate to 1 under physiological conditions; (2) inhibition of type IV cAMP PDE at a fixed time point; and (3) in vivo inotropic activity in anesthetized dogs by both intravenous and oral administration.Release of 1 from 4a (series 1) was found to be too slow to be of value as prodrug of 1, since decarboxylation could be induced only by strong acid, conditions under which hydrolytic ring opening was found to severely compete.Conversely, 1 was released too readily on exposure of (N,N-dialkylamino)methyl derivatives such as 8d (series 2) to physiological conditions, although no large increase in aqueous solubility was realized.Finally, both the physicochemical and in vitro studies indicated that ring closure of the guanidinium esters and amides 17a-k (series 3) to 1 was quantitative and pH- and time-dependent, suggesting the possibility of delivery of the open, water-soluble prodrug form, followed by closure to 1 in plasma.Detailed examination of these agents in vivo, however, demonstrated that only those compounds that rapidly cyclized to 1, as measured by plasma levels of 1, exhibited inotropic activity, indicating that the open prodrug form was not efficiently absorbed upon oral administration.